Active	Status	Sponsor type	Region	Phase	Filter
2 Active 5 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
solengepras (CVN424) / Cerevance
NCT06553027: To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications	Recruiting	3	330	US	CVN424 75 mg, CVN424 150 mg, Placebo	Cerevance	Parkinson Disease	10/25	03/26
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424	Active, not recruiting	2	62	US	CVN424 150 mg, Placebo	Cerevance Beta, Inc.	Parkinson's Disease	10/24	02/25
Target-11 / Cerevance
No trials found
Target-16 / Cerevance
No trials found
Target-17 / Cerevance
No trials found
CVN766 / Cerevance
No trials found
CVN293 / Cerevance
No trials found
Target-18 / Cerevance
No trials found
CVN398 / Cerevance
No trials found
CVN830 / Cerevance
No trials found
C101248 / Cerevance
No trials found